Watson Secures Clearances for Actavis Deal

Skadden represented Watson Pharmaceuticals, Inc. in securing antitrust approvals by the U.S. Federal Trade Commission (on October 15) and the European Commission (on October 5) of its $5.6 billion acquisition of Actavis Group, announced earlier this year.

BACK TO TOP